Posts tagged study
Titan Pharma implant IND cleared for Parkinson’s study

The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson's disease.

Read More
BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for a 12-week period, with a favorable safety profile.

Read More
Soricimed publishes Phase 1 results of SOR-C13

Closely-held Soricimed Biopharma announced publication in the peer-reviewed journal, Investigational New Drugs, The Journal of New Anticancer Agents of its first-in-human Phase 1 study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Read More
Maxim raises Ritter Pharma price target to $5

Maxim Group raised its price target for Ritter Pharmaceuticals (NASDAQ:RTTR) to $5 from $4 ahead of top-line data in the current quarter for a Phase 2b/3 study of RP-G28 for the treatment of lactose intolerance. The stock closed at $3.49 on Feb. 13.

Read More
Stifel downgrades Ocera Therapeutics to hold

Stifel downgraded Ocera Therapeutics (NASDAQ:OCRX) to “hold” from “buy” and slashed its price target to $1 from $9 after the company reported top-line results from a Phase 2b study evaluating ornithine phenylacetate (OCR-002) in hospitalized patients with hepatic encephalopathy (HE).

Read More
HCW upgrades CymaBay to buy

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral” and raised its price target to $6 from $2 after a revision and update of its revenue and valuation models. The stock closed at $1.67 on Jan. 27.

Read More
BTIG starts Intra-Cellular Therapies at buy

BTIG launched coverage of Cellular Therapies (NASDAQ:ITCI) with a “buy” rating and $44 price target, saying there is considerable promise for the company’s antipsychotic, ITI-007, in multiple indications. The stock closed at $15.05 on Dec. 21.

Read More
Roth starts Inotek Pharma at buy

Roth Capital Partners initiated coverage of Inotek Pharmaceuticals (NASDAQ:ITEK) with a “buy” rating and $10 price target. The stock closed at $6.40 on Nov. 30.

Read More
Oramed GLP-1 analog found safe in study

Oramed Pharmaceuticals (NASDAQ:ORMP) has successfully concluded a Phase 1b study of ORMD-0901, its oral GLP-1 analog, in Type 2 diabetes patients.

Read More
Stifel downgrades Alcobra to hold

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult patients with ADHD, known as the “MEASURE” study.

Shares of Alcobra were quoted at $2.55 at midday Friday.

Read More
Cellectar posts new positive data in Phase 1 MM trial

Cellectar Biosciences (NASDAQ:CLRB) reported positive data from the second cohort of patients enrolled in its orphan-drug designated Phase 1 study of CLR 131 in patients with relapsed or refractory multiple myeloma.

Following these outcomes, the study's data monitoring committee approved patient enrollment to the third cohort, which will include a 33% dose increase from the previous cohort.

Read More
Roth cuts GenVec price target to $2

Roth Capital Partners lowered its price target for “buy-rated” GenVec (NASDAQ:GNVC) to $2 from $8, even though the FDA lifted the clinical hold on CGF166, being run worldwide by partner Novartis. The stock closed at 60 cents on Friday.

“This is an important milestone for the GenVec as CGF166 could be the first gene therapy approved for hearing loss,” writes analyst Joseph Pantginis. New patients will be entering cohort 4 in the dose escalation phase and the study is still expected to be complete in 2017.

Read More
Maxim cuts Celsion price target to $4

Maxim Group cut its price target for “buy-rated” Celsion (NYSE:CLSN) to $4 from $9. The stock was quoted at $1.22 Friday afternoon.

“While we are believers in Celsion’s ThermoDox product and platform, we recognize that pivotal Phase 3 data [from the OPTIMA study] will not arrive until late 2018,” writes analyst Jason McCarthy.

Read More
Roth ups Celator Pharma price target to $26

Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday

“This is an important next step for Vyxeos on the path to what we believe is likely approval,” writes analyst Joseph Pantginis.

Read More